| Report ID | 229963 |
| Drug Identification Number | 02409275 |
| Brand name | DOXORUBICIN HYDROCHLORIDE INJECTION |
| Common or Proper name | DOXORUBICIN INJ 10MG/5ML |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVESICAL INTRAVENOUS INTRAVESICAL INTRAVENOUS |
| Packaging size | 5ml |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-06-06 |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-12-02 |
| Company comments | Suspended Supply |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2024-06-07 | French | Compare |
| v1 | 2024-06-07 | English | Compare |